Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Express Scripts
Fish and Richardson
Citi
Healthtrust
Colorcon
Cantor Fitzgerald
Teva

Generated: July 16, 2018

DrugPatentWatch Database Preview

OCUPRESS Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Ocupress, and what generic alternatives are available?

Ocupress is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in OCUPRESS is carteolol hydrochloride. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the carteolol hydrochloride profile page.
Summary for OCUPRESS
Drug patent expirations by year for OCUPRESS
Medical Subject Heading (MeSH) Categories for OCUPRESS
Synonyms for OCUPRESS
(+/-)-Carteolol Hydrochloride
2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, monohydrochloride
2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-,monohydrochloride
2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride
2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2hydroxypropoxy]-3,4-dihydro, monohydrochloride
2(1H)-Quinolinone,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride
5-(2-Hydroxy-3-tert-butylamino)propoxy-3,4-dihydrocarbostyril hydrochloride
5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-2(1H)-quinolinone hydrochloride
5-(3-((tert-Butyl)amino)-2-hydroxypropoxy)-3,4-dihydro-2-quinolone monohydrochloride
5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydrocarbostyril monohydrochloride
5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydroquinolin-2(1H)-one hydrochloride
5-(3-t-butylamino-2-hydroxypropoxy)-3,4-dihydrocarbostyril hydrochloride
5-(3-tert-Butylamino-2-hydroxy-propoxy)-3,4-dihydro-2(1H)-chinolinon-hydrochlorid
5-(3-tert-Butylamino-2-hydroxy-propoxy)-3,4-dihydro-2(1H)-chinolinon-hydrochlorid [German]
5-(3-tert-Butylamino-2-hydroxy)propoxy-3,4-dihydrocarbostyril hydrochloride
5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinolin-2-one hydrochloride
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one hydrochloride
5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydrocarbostyril monohydrochloride
5-[3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone Hydrochloride
51781-06-7 (Parent)
51781-21-6
Abbott 43326
Abbott-43326
AC1L2343
AK387464
AKOS027379166
Arteolol
Arteoptic
B5944
C-35682
C16H24N2O3.HCl
Carbonolol
Carteol
Carteolol (hydrochloride)
Carteolol HCl
carteolol hydrochloride
Carteolol hydrochloride (JP17/USP)
Carteolol hydrochloride [USAN:JAN]
Carteolol hydrochloride [USAN:USP:JAN]
Carteolol(hydrochloride)
Cartrol
Cartrol (TN)
CAS-51781-21-6
CC-05270
CCG-213475
CHEBI:3438
CHEMBL1201002
CS-2955
CTK8F8480
D00599
dl-Carteolol Hydrochloride
DSSTox_CID_25478
DSSTox_GSID_45478
DSSTox_RID_80904
DTXSID4045478
EINECS 257-415-7
Endak
Endak hydrochloride
Endak mite
EX-A1257
FT-0640026
HE357823
HMS1569I14
HY-17495A
KS-00001D9M
LS-142780
Mikelan
Mikelan LA
MLS002153816
MolPort-006-129-555
NCGC00016865-01
NCGC00179541-03
NSC 300906
NSC-300906
NSC-760060
NSC300906
NSC760060
Ocupress (TN)
OPC 1085
OPC-1085
Pharmakon1600-01505519
s4278
SCHEMBL41380
SMR001233186
SR-01000841202
SR-01000841202-2
Teoptic
Tox21_110654
Tox21_110654_1
WLN: T66 BMVT&J GO1YQ1MX1&1&1 &GH

US Patents and Regulatory Information for OCUPRESS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis OCUPRESS carteolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019972-001 May 23, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for OCUPRESS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis OCUPRESS carteolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019972-001 May 23, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis OCUPRESS carteolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 019972-001 May 23, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Teva
US Department of Justice
Harvard Business School
Farmers Insurance
Medtronic
Dow
Cipla
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.